Operating Lease, Right-of-Use Asset of ArriVent BioPharma, Inc. from 31 Dec 2023 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
ArriVent BioPharma, Inc. quarterly Operating Lease, Right-of-Use Asset in USD history and change rate from 31 Dec 2023 to 31 Dec 2025.
  • ArriVent BioPharma, Inc. Operating Lease, Right-of-Use Asset for the quarter ending 31 Dec 2025 was $13,000, a 92% decline year-over-year.
Source SEC data
View on sec.gov
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Change (%)

ArriVent BioPharma, Inc. Quarterly Operating Lease, Right-of-Use Asset (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $13,000 -$141,000 -92% 31 Dec 2025 10-K 05 Mar 2026 2025 FY
Q3 2025 $49,000 -$138,000 -74% 30 Sep 2025 10-Q 10 Nov 2025 2025 Q3
Q2 2025 $85,000 -$134,000 -61% 30 Jun 2025 10-Q 11 Aug 2025 2025 Q2
Q1 2025 $120,000 -$130,000 -52% 31 Mar 2025 10-Q 12 May 2025 2025 Q1
Q4 2024 $154,000 -$137,000 -47% 31 Dec 2024 10-K 05 Mar 2026 2025 FY
Q3 2024 $187,000 30 Sep 2024 10-Q 14 Nov 2024 2024 Q3
Q2 2024 $219,000 30 Jun 2024 10-Q 14 Aug 2024 2024 Q2
Q1 2024 $250,000 31 Mar 2024 10-Q 08 May 2024 2024 Q1
Q4 2023 $291,000 31 Dec 2023 10-K 03 Mar 2025 2024 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.